Related Experiment Video
Updated: Jan 11, 2026
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Advances in Cancer Vaccines for Digestive System Cancers: A Systematic Analysis of Clinical Trials
1Graduate School, Heilongjiang University of Chinese Medicine, Harbin, People's Republic of China.
Purpose:
Digestive system cancers, including gastric, liver, pancreatic, and colorectal cancers, are the leading causes of cancer-related deaths worldwide. Conventional treatments, such as surgery and chemotherapy, have limited efficacy in the treatment of advanced digestive system cancers, necessitating the development of new and effective therapeutic strategies. This study review aimed to evaluate the potential of cancer vaccines in the treatment of digestive system cancers and explore the prospects for the clinical application of different vaccine types.
Methods:
We analyzed data from clinical trials of cancer vaccines related to cancers of the digestive system. The screening criteria included data on the trial design, therapeutic targets, efficacy, and safety.
Results:
A total of 165 clinical trials that met the inclusion criteria were screened, mainly investigating nucleic acid and peptide vaccines, with the largest number of vaccine studies targeting colorectal and pancreatic cancers. Trial results demonstrated that cancer vaccines have the potential to treat cancers of the digestive system, with the particular advantages of enhancing immune responses and reducing tumor resistance.
Conclusion:
Cancer vaccines, particularly nucleic acid and peptide vaccines, demonstrate potential as therapeutic interventions for digestive system cancers. Nucleic acid vaccines offer advantages in scalability and rapid design; however, they face limitations in delivery efficiency and immune activation. In contrast, peptide vaccines are safer and more stable than nucleic acid ones; however, they often elicit comparatively weaker immune responses. Therefore, it is essential to address platform-specific challenges. Future clinical trials should be strategically designed to evaluate and optimize these distinct platforms to accelerate their translation to clinical applications.
Insights
Cancer vaccines, especially nucleic acid and peptide types, show promise for treating digestive system cancers by boosting immune response. Further research is needed to overcome platform-specific challenges for clinical use.
Area of Science:
- Oncology
- Immunology
- Vaccinology
Background:
- Digestive system cancers are a major global health burden, with limited success from conventional treatments like surgery and chemotherapy.
- Advanced stages of these cancers necessitate novel therapeutic strategies.
- Cancer vaccines represent a promising avenue for improving treatment outcomes.
Purpose of the Study:
- To review the potential of cancer vaccines in treating digestive system cancers.
- To explore the clinical application prospects of various cancer vaccine types.
- To identify challenges and future directions for vaccine development in this field.
Main Methods:
- Systematic review of clinical trials involving cancer vaccines for digestive system cancers.
- Screening of trials based on design, therapeutic targets, efficacy, and safety data.
- Analysis of 165 eligible clinical trials.
Main Results:
- Nucleic acid and peptide vaccines were the primary types investigated, with a focus on colorectal and pancreatic cancers.
- Cancer vaccines demonstrated potential in enhancing immune responses and overcoming tumor resistance.
- A significant number of clinical trials (165) met the inclusion criteria.
Conclusions:
- Nucleic acid and peptide vaccines show therapeutic potential for digestive system cancers.
- Nucleic acid vaccines offer scalability but face delivery and activation challenges; peptide vaccines are safer but may induce weaker responses.
- Optimizing platform-specific strategies and designing future clinical trials are crucial for successful translation to clinical practice.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
01:21Cancer Survival Analysis
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers